Abstract
The field of cardio-oncology has emerged in response to the increased risk of cardiovascular disease (CVD) in patients with cancer. However, recent studies suggest a more complicated CVD-cancer relationship, wherein development of CVD, either prior to or following a cancer diagnosis, can also lead to increased risk of cancer and worse outcomes for patients. In this review, we describe the current evidence base, across epidemiological as well as preclinical studies, which supports the emerging concept of ‘reverse-cardio oncology’, or CVD-induced acceleration of cancer pathogenesis.
| Original language | English |
|---|---|
| Pages (from-to) | 1-8 |
| Number of pages | 8 |
| Journal | Journal of Molecular and Cellular Cardiology |
| Volume | 163 |
| DOIs | |
| Publication status | Published - Feb 2022 |
| Externally published | Yes |
Bibliographical note
Funding Information:Drs. Aboumsallem and de Boer are supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). This work was further supported by grants from the Netherlands Heart Foundation (CVON SHE-PREDICTS-HF, grant 2017–21; CVON RED-CVD, grant 2017–11; CVON PREDICT2 , grant 2018–30; and CVON DOUBLE DOSE, grant 2020B005), and by a grant from the leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN). Dr. Moore is supported by the National Institutes of Health ( R35HL135799 and P01HL131481 ).
Funding Information:
Drs. Aboumsallem and de Boer are supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). This work was further supported by grants from the Netherlands Heart Foundation (CVON SHE-PREDICTS-HF, grant 2017?21; CVON RED-CVD, grant 2017?11; CVON PREDICT2, grant 2018?30; and CVON DOUBLE DOSE, grant 2020B005), and by a grant from the leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN). Dr. Moore is supported by the National Institutes of Health (R35HL135799 and P01HL131481).
Publisher Copyright:
© 2021 The Authors
